- Everyday Alpha
- Posts
- The Heart Drug Launch That Could Deliver 95% Upside From Here
The Heart Drug Launch That Could Deliver 95% Upside From Here
One quiet cardiac rollout is rewriting the ceiling on a mid-cap biotech's stock
A cardiac drug launched late last year is scaling faster than the Street modeled, and one mid-cap biotech is carrying the whole story.
A top-ranked analyst just reiterated a target roughly 95% above where the stock trades today, with the next launch update only two weeks out.
Grid alert (Sponsored)
One analyst believes America's aging power grid has become one of the biggest risks facing investors today.
As electricity demand continues to climb, he says growing pressure on critical infrastructure could have far-reaching consequences for both the economy and the stock market.
In his latest free presentation, he explains what's driving the concern, the sectors he believes could be most affected, and the steps he says investors should consider to help prepare their portfolios.
Watch the Free Presentation
BridgeBio Pharma
August 3 – Pre‑market
Ticker: BBIO | Sector: Healthcare (Biotech) | Market Cap: ~$15-16B
30‑Second Take
Why now? BridgeBio launched Attruby, its ATTR-cardiomyopathy drug, late last year. The ramp is what's driving this story.
Wall Street is looking for revenue to nearly double this year to around $960 million, with another leg higher in 2027 as scripts scale.
Cantor Fitzgerald's Louise Chen just reiterated her overweight rating with a $157 price target. That's roughly 95% upside from where BBIO trades today.
This isn't a hype trade. It's a real drug, a real market (ATTR-CM is a $10B-plus opportunity), and a real launch you can track quarter by quarter.
Trade Setup
Time frame: 6 to 12 months
Edge type: Post-launch catalyst ramp with analyst PT expansion
You're not betting on a binary FDA decision here. That part's done.
What you're betting on is the Attruby launch trajectory beating conservative Street models, and driving upward revisions to revenue and EPS over the next 2 to 3 quarters.
The setup is a classic mid-cap biotech transition. Cash-burning developer flips to commercial-stage cash generator. When that flip happens cleanly, the multiple re-rates hard.
Add in a competitor label (Pfizer's tafamidis) that Attruby's clinical data may outperform, and you have a story that could work even if the broader market stalls.
The Wealth Strategy (Sponsored)
His reported salary? $400,000 annually.
Yet the bigger number tells a different story: Up to $250,000 each month… from one channel.
It’s not property. It’s not stocks.
So what’s behind this kind of consistent income — and why is it catching attention right now?
Poll: Looking back at your investing year so far, what would you most change? |
Snapshot Table
Metric | Value | Current Stance |
|---|---|---|
Price | $79.96 | Well below Cantor's $157 PT |
52‑week range | $42.09 to $93.42 | Mid-range, roughly 14% below the high |
Market Cap | ~$15-16B | Mid-cap sweet spot |
P/E Ratio | N/A (not yet profitable) | Valuation on revenue and pipeline |
Avg Daily Volume | ~3.1M shares (3-month avg) | Liquid enough for position sizing |
Next Catalyst | Q2 earnings and Attruby launch update, expected mid-August | Within 2 weeks |
Chart
1-Month Trading Summary: BBIO has been base-building ahead of the Q2 update, with Attruby script data providing the fundamental support.
Watch for volume expansion on any close above recent resistance. That's often the first tell that institutions are positioning ahead of the launch numbers.
Bull Case
Core thesis: BBIO isn't a will-the-drug-work story anymore. Attruby (acoramidis) is approved, launched, and generating revenue right now.
The bull case is simple. The launch is going better than the Street modeled, and the numbers are about to prove it.
Catalysts: The ATTR-CM market itself is the tailwind. Transthyretin amyloid cardiomyopathy is dramatically underdiagnosed, and as cardiologists learn to look for it, the treatable patient population keeps expanding.
Pfizer's tafamidis (Vyndaqel/Vyndamax) built a multi-billion-dollar franchise on this exact dynamic. Attruby is now the second entrant, and its ATTRibute-CM trial data on all-cause mortality gave it a differentiated marketing angle.
Valuation upside: Chen isn't a random bull. She's one of the most-followed biotech analysts on the Street, and her $157 target is a real number, not a moonshot.
If she's right and revenue doubles to $960M this year with another sharp step-up in 2027, the current market cap looks like a bargain on standard commercial-stage biotech multiples.
Then there's the pipeline. Attruby is the anchor, but BBIO still has multiple mid- and late-stage programs, giving you optionality on top of the core thesis.
What I like most is that the catalyst path is dense and specific. Q2 earnings and launch update in mid-August. Then Q3 in November. Every 90 days, you get a fresh print to reprice against.
Bear Case
Now the risks, because you need to know what could blow this up.
Launch execution risk is real. Every launch story looks great until it doesn't. If Attruby scripts come in soft in Q2, the stock gets hit hard, analyst targets get cut, and the re-rating thesis stalls.
Post-launch biotechs live and die on the trajectory of the first four quarters.
Then there's competitive pressure. Pfizer's tafamidis has years of physician relationships and payer contracts already locked in. Attruby has to displace an entrenched incumbent, and that takes time. Alnylam's vutrisiran is also in the mix.
Biotech multiples are volatile too. If the sector rolls over on macro (rate expectations, risk-off), BBIO gets caught up in it regardless of company-specific news.
Finally, the balance sheet. BBIO burned cash for years to get here. Even with Attruby revenue ramping, you'll want to see the cash runway extending, not shrinking.
If you're going to own it, size it accordingly. This is a mid-cap biotech, not a utility.
Quick Checklist
✅ Thesis still valid after today's close
✅ Volume confirms move above key levels
✅ Q2 earnings and Attruby launch update confirmed for mid-August
Deep‑Dive Links
That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned!
Best Regards,
—Noah Zelvis
Everyday Alpha